[Procedure for radiation control and inspection method of zevalin radioimmunotherapy].
Takahashi
Yasuyuki
Y
Et Al
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D018951:Antigens, CD20; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy; D017744:Medical Waste Disposal; D011829:Radiation Dosage; D011835:Radiation Protection / Q000379:methods*; D011850:Radioactive Waste / Q000517:prevention & control; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D017751:Safety Management / Q000379:methods*
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D017744:Medical Waste Disposal; D011850:Radioactive Waste; D019275:Radiopharmaceuticals; C422802:ibritumomab tiuxetan